Saccharomyces Boulardii Ameliorates LPS-Induced Amyloidogenesis in Rats

Overview

Journal Probiotics Antimicrob Proteins

Publisher Springer

Specialties Infectious Diseases
Microbiology
Nutritional Sciences
Pharmacology

Date 2024 Dec 31

PMID 39739163

Authors

Ghazaleh Mohammadi

Fatemeh Babaei

Faezeh Golpour

Fatemeh Sadat Rashidi

Shiva Ghafghazi

Leila Dargahi

Marjan Nassiri-Asl

Affiliations

Soon will be listed here.

Abstract

Gut brain axis can affect the incidence of Alzheimer's disease (AD). Probiotics restore the homeostasis of gut dysbiosis and prevent AD. Here, we evaluated the impact of Saccharomyces boulardii on rats with lipopolysaccharide (LPS)-induced amyloidogenesis. Rats were classified into four groups: (1) Control (saline), (2) LPS 250 µg/kg (saline + LPS), (3) S. boulardii (10 CFU/mL/rat), and (4) S. boulardii (10 CFU/mL/rat) + LPS (250 μg/kg). The passive behavioral test, Western blotting, and immunohistochemistry were done using the animal hippocampi. Step-through latency (STL) indicated that the LPS-treated group had decreased memory retrieval compared to the control group. The LPS group had increased hippocampal levels of amyloid-β peptide, amyloid-β precursor protein (APP), and β-secretase (BACE). Administration of the S. boulardii before LPS prolonged STL which has been shortened in the LPS group (P < 0.05). In the LPS + S group, S. boulardii reduced the levels of APP significantly compared to the LPS group (P < 0.01). S. boulardii mitigated Aβ buildup and memory dysfunction caused by LPS through modulating the APP, BACE1, and Aβ pathways. Future studies are required to explain the neuroprotective effects of S. boulardii, since it could be a novel therapy or prevention strategy for AD.

References

Ma C, Hong F, Yang S . Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules. 2022; 27(4). PMC: 8876037. DOI: 10.3390/molecules27041210. View

Arvanitakis Z, Shah R, Bennett D . Diagnosis and Management of Dementia: Review. JAMA. 2019; 322(16):1589-1599. PMC: 7462122. DOI: 10.1001/jama.2019.4782. View

Nava Catorce M, Gevorkian G . LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals. Curr Neuropharmacol. 2015; 14(2):155-64. PMC: 4825946. DOI: 10.2174/1570159x14666151204122017. View

Dinel A, Andre C, Aubert A, Ferreira G, Laye S, Castanon N . Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome. PLoS One. 2011; 6(9):e24325. PMC: 3174932. DOI: 10.1371/journal.pone.0024325. View

Badshah H, Ali T, Kim M . Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4/NFκB signaling pathway. Sci Rep. 2016; 6:24493. PMC: 4837357. DOI: 10.1038/srep24493. View

Lee J, Lee Y, Yuk D, Choi D, Ban S, Oh K . Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation. 2008; 5:37. PMC: 2556656. DOI: 10.1186/1742-2094-5-37. View

Thapa A, Jett S, Chi E . Curcumin Attenuates Amyloid-β Aggregate Toxicity and Modulates Amyloid-β Aggregation Pathway. ACS Chem Neurosci. 2015; 7(1):56-68. DOI: 10.1021/acschemneuro.5b00214. View

Czerniawski J, Guzowski J . Acute neuroinflammation impairs context discrimination memory and disrupts pattern separation processes in hippocampus. J Neurosci. 2014; 34(37):12470-80. PMC: 4160778. DOI: 10.1523/JNEUROSCI.0542-14.2014. View

Qin J, Li R, Raes J, Arumugam M, Burgdorf K, Manichanh C . A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285):59-65. PMC: 3779803. DOI: 10.1038/nature08821. View

10.

Cryan J, Dinan T . Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012; 13(10):701-12. DOI: 10.1038/nrn3346. View

11.

Bauer K, Huus K, Finlay B . Microbes and the mind: emerging hallmarks of the gut microbiota-brain axis. Cell Microbiol. 2016; 18(5):632-44. DOI: 10.1111/cmi.12585. View

12.

Kim N, Yun M, Oh Y, Choi H . Mind-altering with the gut: Modulation of the gut-brain axis with probiotics. J Microbiol. 2018; 56(3):172-182. DOI: 10.1007/s12275-018-8032-4. View

13.

Umbrello G, Esposito S . Microbiota and neurologic diseases: potential effects of probiotics. J Transl Med. 2016; 14(1):298. PMC: 5069982. DOI: 10.1186/s12967-016-1058-7. View

14.

Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C . Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2016; 49:60-68. DOI: 10.1016/j.neurobiolaging.2016.08.019. View

15.

Zhao Y, Jaber V, Lukiw W . Secretory Products of the Human GI Tract Microbiome and Their Potential Impact on Alzheimer's Disease (AD): Detection of Lipopolysaccharide (LPS) in AD Hippocampus. Front Cell Infect Microbiol. 2017; 7:318. PMC: 5504724. DOI: 10.3389/fcimb.2017.00318. View

16.

Zilberter Y, Zilberter M . The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. J Neurosci Res. 2017; 95(11):2217-2235. DOI: 10.1002/jnr.24064. View

17.

Bostanciklioglu M . The role of gut microbiota in pathogenesis of Alzheimer's disease. J Appl Microbiol. 2019; 127(4):954-967. DOI: 10.1111/jam.14264. View

18.

Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti G . Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother. 2017; 18(1):83-90. PMC: 5958896. DOI: 10.1080/14737175.2018.1400909. View

19.

Friedland R, Chapman M . The role of microbial amyloid in neurodegeneration. PLoS Pathog. 2017; 13(12):e1006654. PMC: 5739464. DOI: 10.1371/journal.ppat.1006654. View

20.

Xu R, Wang Q . Towards understanding brain-gut-microbiome connections in Alzheimer's disease. BMC Syst Biol. 2016; 10 Suppl 3:63. PMC: 5009560. DOI: 10.1186/s12918-016-0307-y. View